Clinical Trial Update: Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dexmedetomidine for agitation associated with schizophrenia and bipolar disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Bipolar Ii Disorder
• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• PRECEDEX (DEXMEDETOMIDINE HYDROCHLORIDE)

Snippet

Sponsor: BioXcel Therapeutics Inc | Conditions: Agitation,Psychomotor, Bipolar I Disorder | Phase 3 | Status: COMPLETED